

Withdrawn adverse event

Group by
Anti-TNFα

Study name

Statistics for each study

Events / Total

Risk ratio and 95% CI

		Risk ratio	Lower limit	Upper limit	Anti-TNFα	Control
Adalimumab	Weinblatt et al, 2003 (29)	0.74	0.15	3.73	5 / 209	2 / 62
Adalimumab	van de Putte et al, 2004 (30)	2.15	0.51	9.19	17 / 434	2 / 110
Adalimumab	Furst et al, 2003 (31)	1.13	0.44	2.88	9 / 318	8 / 318
Adalimumab	Keystone et al, 2004 (32)	1.54	0.85	2.81	42 / 419	13 / 200
Adalimumab	Breedveld et al, 2006 (33)	1.45	0.88	2.38	58 / 542	19 / 257
Adalimumab		1.42	1.01	1.99		
Etanercept	Moreland et al, 1999 (24)	1.21	0.32	4.56	7 / 154	3 / 80
Etanercept	Weinblatt et al, 1999 (25)	1.02	0.10	10.77	2 / 59	1 / 30
Etanercept	Bathon et al, 2000 (26)	0.50	0.29	0.87	23 / 415	24 / 217
Etanercept	van der Heijde et al, 2006 (28)	0.76	0.54	1.06	71 / 454	47 / 228
Etanercept		0.70	0.53	0.92		
Infliximab	Lipsky et al, 2000 (19)	0.96	0.43	2.14	26 / 340	7 / 88
Infliximab	St Clair et al, 2004 (20)	3.04	1.54	6.01	69 / 751	9 / 298
Infliximab	Quinn et al, 2005 (22)	3.00	0.14	65.90	1 / 10	0 / 10
Infliximab	Westhovens et al, 2006 (23)	2.39	1.13	5.07	38 / 721	8 / 363
Infliximab		2.04	1.34	3.12		
Overall		1.25	0.65	2.39		

